Champions Oncology Dividend
Dividend criteriumcontroles 0/6
Champions Oncology does not have a record of paying a dividend.
Belangrijke informatie
n/a
Dividendrendement
-0.4%
Terugkoop Rendement
| Totaal aandeelhoudersrendement | -0.4% |
| Toekomstig dividendrendement | n/a |
| Dividendgroei | n/a |
| Volgende betaaldatum dividend | n/a |
| Ex-dividenddatum | n/a |
| Dividend per aandeel | n/a |
| Uitbetalingsratio | n/a |
Recente dividendupdates
Geen updates
Recent updates
Companies Like Champions Oncology (NASDAQ:CSBR) Can Afford To Invest In Growth
Oct 24
It's A Story Of Risk Vs Reward With Champions Oncology, Inc. (NASDAQ:CSBR)
Jun 14Is Now The Time To Put Champions Oncology (NASDAQ:CSBR) On Your Watchlist?
Sep 28Champions Oncology Non-GAAP EPS of -$0.02, revenue of $12.9M
Jul 21We Think Some Shareholders May Hesitate To Increase Champions Oncology, Inc.'s (NASDAQ:CSBR) CEO Compensation
Oct 14We Think Champions Oncology (NASDAQ:CSBR) Can Afford To Drive Business Growth
Jun 21Are Investors Undervaluing Champions Oncology, Inc. (NASDAQ:CSBR) By 44%?
Apr 09Here's Why We're Not At All Concerned With Champions Oncology's (NASDAQ:CSBR) Cash Burn Situation
Mar 19The Champions Oncology (NASDAQ:CSBR) Share Price Has Gained 243%, So Why Not Pay It Some Attention?
Mar 02Is There Now An Opportunity In Champions Oncology, Inc. (NASDAQ:CSBR)?
Feb 04Do Insiders Own Lots Of Shares In Champions Oncology, Inc. (NASDAQ:CSBR)?
Jan 14Philip Breitfeld Is The Chief Strategy & Innovation Officer and Director of Champions Oncology, Inc. (NASDAQ:CSBR) And They Just Sold 100% Of Their Shares
Dec 19Champions Oncology, Inc. (NASDAQ:CSBR) Analysts Are Pretty Bullish On The Stock After Recent Results
Dec 16
Champions Oncology beats on revenue
Dec 14Estimating The Fair Value Of Champions Oncology, Inc. (NASDAQ:CSBR)
Dec 04Stabiliteit en groei van betalingen
Dividenden ophalen
Stabiel dividend: Insufficient data to determine if CSBR's dividends per share have been stable in the past.
Groeiend dividend: Insufficient data to determine if CSBR's dividend payments have been increasing.
Dividendrendement versus markt
| Champions Oncology Dividendrendement versus markt |
|---|
| Segment | Dividendrendement |
|---|---|
| Bedrijf (CSBR) | n/a |
| Markt onderkant 25% (US) | 1.5% |
| Markt Top 25% (US) | 4.5% |
| Gemiddelde industrie (Life Sciences) | 0.5% |
| Analist prognose (CSBR) (tot 3 jaar) | n/a |
Opmerkelijk dividend: Unable to evaluate CSBR's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
Hoog dividend: Unable to evaluate CSBR's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Winstuitkering aan aandeelhouders
Verdiendekking: Insufficient data to calculate CSBR's payout ratio to determine if its dividend payments are covered by earnings.
Contante uitbetaling aan aandeelhouders
Kasstroomdekking: Unable to calculate sustainability of dividends as CSBR has not reported any payouts.